To include your compound in the COVID-19 Resource Center, submit it here.

Aug. 6 Company Quick Takes: Sales updates from Alnylam, Sage, Regeneron and GW; plus regulatory updates from MorphoSys and more

Alnylam's Onpattro bests consensus
Sales of amyloidosis therapy Onpattro patisiran from Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) reached $38.2 million in 2Q19, the drug's third full quarter on the market. The figure beat analysts' consensus of $32 million, and is 45% higher than Onpattro's 1Q19 sales of $26.3 million. Alnylam launched Onpattro, the world's first approved RNAi therapeutic, in August 2018 (see "Agreement to Differ").

First

Read the full 629 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE